FACTBOX-Top biotech takeout targets of 2010 -Morningstar
Tue Mar 9, 2010 2:29pm EST
NEW YORK, March 9 (Reuters) - Here are the biotechnology companies most likely to be bought in 2010, according to analysts at Morningstar.
In assessing odds of a takeover, Morningstar said it weighed drug portfolio strength, fits with potential partners, profit-boosting power and financial health.
In pursuing acquisitions, product-hungry pharmaceutical companies appear increasingly undeterred by partnerships biotech companies have with rival drugmakers. [ID:nN09215904]
Many on Morningstar's list, including Vertex, Auxilium and Human Genome, have partnerships on their most promising drugs.
Here are the takeout targets with market value:
1) Vertex, $8.3 billion
2) Auxilium Pharma, $1.5 billion
3) Human Genome Sciences, $5.8 billion
4) InterMune, $1.3 billion
5) Celgene, $28.3 billion
6) Exelixis, $730 million
7) Genzyme, $15.2 billion
8) Crucell, $1.7 billion
9) Elan, $4.2 billion
10) BioMarin, $2.3 billion |
